unknown by Milo, Simcha
more, if this mitral stentless valve is implanted in a child and
the heart grows, the chordae are pulled down toward the ven-
tricle, preventing the normal movement of the cusps. In both
cases, the mitral chordae ruptured because of undue tension.
Nonmoving cusps will eventually calcify as well.
Interestingly, in 1 child the aortic valve had a minimal amount
of calcification, and the second child had a normal valve 3
years after the operation. The valve was not explanted and is
still functioning well years after the operation.
I differ with Milo and associates about the causes of calcifi-
cation of the BioCor mitral valve treated with the No-React for-
mula. The BioCor stentless mitral valve is an unproved design.
Its implantation and proper function depend on many factors,
which can cause the valve to stop moving or even tear without
any degeneration. The fact that these patients had severe endo-
carditis could also be a factor that caused inflammation or sub-
clinical endocarditis followed obviously by calcification.
Clinical experience with BioCor stentless valves treated with
the No-React formula so far shows that these valves resist cal-
cification. Von Oppell and coworkers1 recently presented an
experience with the BioCor No-React stentless aortic valve in
52 consecutive patients. The mean age was 44 ± 17 years, and
the youngest patient was 16 years at the time of implantation.
The follow-up period is already 5 years (first implant in 1994).
Although this population is considered to be very young for a
bioprosthesis, no calcification has been seen yet. 
Clinical experience with the pulmonic porcine valve con-
duit treated with the No-React formula has been reported in
infants younger than 1 year, with a follow-up period of 18
months. No calcification has been seen so far.2 In these young
children calcification of homografts can be seen as early as 4
months after implantation.3 The fact that the aortic stentless
valve treated with the No-React formula resisted calcification
whereas the BioCor mitral stentless valve did not, in the same
patients, gives further credence to the claim that anticalcifica-
tion treatment cannot compensate for nonfunctioning or
infected valves. I believe that when there is a need to implant
a bioprosthesis in the mitral position in young patients, it
should be a proven design. 
The stentless mitral xenograft is a complex valve that needs
more evaluation. It should not be recommended for use in
children. The conclusions of Milo and associates I believe
should concentrate on the difference between the aortic and
mitral stentless valves in the presence of endocarditis. After
all, if the native valve calcifies after an infection, it will be
presumptuous to expect any anticalcification treatment to be
superior to the patient’s own native tissue.
Shlomo Gabbay, MD
Department of Cardiothoracic Surgery
University of Medicine and Dentistry of New Jersey
New Jersey Medical School
185 South Orange Ave
Newark, NJ 07103-2757
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Reply to the Editor:
Dr Gabbay was deeply involved in choosing the type of
stentless valves used in these 2 children and in observing
them after the operation. We informed him of the results of all
echocardiographic studies done on the children. Early post-
operative studies in the 2 children showed that both leaflets of
the stentless mitral valves had a full spectrum of movement
and that both coaptation and closure were good. In fact, an
inexperienced observer could barely recognize an implanted
prosthesis in the mitral position. Furthermore, one of the
authors (Dr Bar-El) was invited to present these promising
early results at the 1996 meeting of The Society of Thoracic
Surgeons at Gabbay’s presentation on the No-React detoxifi-
cation process (Shelhigh Inc, Millburn, NJ).1 One month
later, as the children’s hearts began to recover and return to
near normal size, we noted a progressive prolapse of both
leaflets. As the prolapse steadily increased, we began to con-
sider replacing the valves, not because of the length of the
chordae tendineae, but because of the prolapse itself.
However, calcification, not the prolapse, determined the time
of surgical intervention. Our follow-up echocardiographic
data do not support Gabbay’s contention that torn chordae
resulted from undue tension. We believe that the early
biodegradation of the valve resulted in calcification, which
led to rupture of the chordae.
We do believe that a stentless mitral prosthesis that incor-
porates the entire subvalvular apparatus may cause problems
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Fig 1. The BioCor stentless mitral valve. It is apparent how
short the chordae are. Since the length of these chordae is
fixed and limited, mismatch can occur leading to chordal rup-
ture or stiffening. The relatively large amount of pericardial
tissue used to strengthen the chordae causes further limitation
in the movement of the cusps.
when implanted in hearts that may eventually change size.
Our results with the No-React–treated BioCor stented and
stentless valves (BioCor, Belohorizonte, Brazil) in adults cor-
relate with those of Von Oppell and associates2 but are not
different from results obtained with valves in which the glu-
taraldehyde was not rinsed out. Massetti and associates3
reported that No-React pulmonic porcine valve conduits they
implanted in children were free from calcification at 18
months, and we are hopeful that the valves will remain so for
several years. In our study, the valves were free from calcifi-
cation at 18 months too. However, on June 11, 1999, we had
to explant the last stentless BioCor No-React–treated aortic
valve on an emergency basis because of rupture of 2 of its
cusps (Fig 1). The left and right coronary cusps had entirely
disintegrated at the free edges, but we saw no evidence of cal-
cification. The condition of the valve caused acute and severe
aortic incompetence. We may learn about the need to detoxi-
fy the tissues and the potential effect on its mechanical prop-
erties from this last patient.
Simcha Milo, MD
Department of Cardiac Surgery
Rambam Medical Center
Haifa 35254, Israel
R E F E R E N C E S
1. Abolhoda A, Yu S, Oyarzun JR, et al. No-React detoxification
process: a superior anticalcification method for bioprostheses.
Ann Thorac Surg 1996;62:1724-30.
2. Von Oppell U, Stemmet F, Brink J, LeVetan B, Heijke S. BioCor
No-React stentless aortic valve: short term results. Presented at
the Stentless Bioprostheses Third International Symposium.
1999; May 12-16 (abstract).
3. Massetti P, Ussia GP, Gazzolo D, Marianeschi MS, Abella FR,
Cipriani A, et al. Aortic pulmonary autograft implant: medium
term follow-up with a note on a new right ventricular pulmonary
artery conduit. J Card Surg 1998;13:173-6.
12/8/100892
Percutaneous treatment of acute aortic dissection
To the Editor:
Acute aortic dissection is frequently a surgical emergency.
The recent publications of nonsurgical treatment with
catheter-delivered endovascular stent-grafts by the Stanford
group1,2 and the German-Italian group3 cast a new light on
the approach to this life-threatening disease. These studies
represent a milestone in the treatment of aortic dissection.
Cardiovascular catheterization and angiography are no
longer for diagnosis only. They have blossomed into thera-
peutic applications and become an integral part of therapeu-
tic interventions in both cardiac and vascular diseases. The
Stanford experiences also represent a multi-disciplinary
effort involving both cardiovascular surgeons and interven-
tional radiologists. Stent-graft placement requires state-of-
the-art image technology, as well as precise manipulation of
the catheter and positioning of the stent.4 The results are very
promising and the future looks bright. We await more patients
to receive such innovative percutaneous treatment and their
long-term results.
Tsung O. Cheng, MD
Professor of Medicine
The George Washington University
Washington, DC 20037
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Fig 1. Cusps of explanted BioCor stentless aortic valve treated
with the No-React formula, which was implanted 5 years
ago. Note disintegration of 2 of the cusps.
